Specialists in quantifying the current and future burden of non-communicable and rare genetic diseases.
Our data-driven epidemiology generates evidence to support strategic planning and portfolio management at each stage of the drug development process, helping to bring new therapies to patients faster.
From molecule to market, our solutions can help.
Deep expertise in disease epidemiology combined with entrepreneurial vision. Our work has been widely published and peer-reviewed by world-leading experts.
Why Us?We’ve spent over a decade developing our methodology to help you ask the right questions and make the best decisions.
SolutionsWe’ve answered all kinds of questions for many different organisations, covering over 25 NCDs and rare genetic diseases in over 80 countries.
Track RecordOur experienced and multidisciplinary team brings together epidemiologists, geneticists, mathematicians, data scientists, researchers, and software engineers.
About UsHealthLumen has today announced the launch of AlleleAtlas, the genetic variant prevalence projection tool. The tool has been developed to bring a valuable resource to the rare disease community, including those engaged in rare disease research and therapeutics in the pharmaceutical, biotech and research spaces, and for patient advocacy organisations aiming to raise awareness.
ReadNovember 14th marks World Diabetes Day, a powerful opportunity to raise awareness of diabetes as a major global health issue. This year’s theme, “Breaking Barriers, Bridging Gaps”, calls for action to reduce diabetes risk factors and ensure equitable access to quality treatment worldwide [1]. The global diabetes crisis: A growing challenge Diabetes currently impacts over […]
ReadStudy highlights which health policies are most likely to be effective in decreasing the prevalence of obesity, with fiscal policies expected to be particularly cost beneficial. This research has informed Nesta’s digital Blueprint tool – which provides data on the health, economic, and feasibility impacts of various obesity interventions – aligning with Nesta’s mission of halving obesity rates in the UK by 2030.
ReadHealthLumen are looking forward to discussing our work on the prevalence of rare diseases and engaging with colleagues dedicated to accelerating rare disease therapeutics at several upcoming conferences in the final quarter of this year.
Read